Ginkgo Bioworks Holdings, Inc. (DNA)
Chart Events
Performance Outlook
| Previous Close | 1.2300 |
| Open | 1.2250 |
| Bid | 0.0000 x 34100 |
| Ask | 0.0000 x 41800 |
| Day's Range | 1.1650 - 1.2600 |
| 52 Week Range | 1.1650 - 4.9100 |
| Volume | |
| Avg. Volume | 20,752,106 |
| Market Cap | 2.497B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2600 |
| Earnings Date | Mar 01, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.59 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DNA
Related Research
- Ginkgo Bioworks Holdings, Inc.Daily – Vickers Top Buyers & Sellers for 10/21/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat5 months agoArgus Research
- PR Newswire
Ginkgo Bioworks Announces Participation in Cowen's 43rd Annual Health Care Conference
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today that Co-Founder and CEO Jason Kelly is scheduled to participate in Cowen's 43rd Annual Health Care Conference, including:
- PR Newswire
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2022. The update, including a webcast slide presentation with additional details on the fourth quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.
- GlobeNewswire
Cronos Group Reports 2022 Fourth Quarter and Full-Year Results
Consolidated net revenue increased 23% in Full Year 2022 compared to Full Year 2021; on a constant currency basis consolidated net revenue increased 28% in Full Year 2022 compared to Full Year 2021 Net revenue in Israel increased 128% in Full Year 2022 compared to Full Year 2021; on a constant currency basis net revenue in Israel increased 137% in Full Year 2022 compared to Full Year 2021 Ended 2022 with $878 million in cash and short-term investments Spinach® became the number one edible brand
